Radioactive treatment for neuroblastoma and other nerve tumors
Part of Cancer clinical trials.
This trial provides access to a radioactive medicine called 131I-MIBG for people with certain nerve tumors that have returned or not responded to standard treatment. The treatment targets and kills cancer cells, and it may help when other options have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of nerve tumor called neuroblastoma that has not responded to standard treatment or has come back, or you are under 12 years old with a pheochromocytoma or paraganglioma that surgery cannot remove.
- You must be at least 12 months old and be able to follow safety rules during treatment, with help from calming medicine if needed.
- Your disease must have continued to grow despite standard therapy like chemotherapy, radiation, or surgery, or it must have come back at any time. Evaluations must be done within 8 weeks before the study starts.
- You need to have saved stem cells that can be given back after treatment. If you don't have them, the treatment dose may be lower.
- You must have recovered from side effects of previous treatments, including waiting at least 2 weeks after other anti-cancer treatments, 3 months after certain types of radiation, and 6 weeks after any previous MIBG therapy.
- Your liver, kidneys, blood counts, and heart must be working well enough. For example, your creatinine (a kidney marker) must be within 2 times the normal upper limit, and your infection-fighting cells (ANC) must be at least 750, unless you have saved stem cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation (MIBG) with two medicines, vorinostat and dinutuximab, for children and young adults with high-risk neuroblastoma that has returned or not fully responded to earlier treatment. The goal is to see if adding these medicines helps the radiation work better and improves outcomes.
This trial uses a radioactive medicine called 131I-MIBG to treat neuroblastoma or pheochromocytoma that has come back or not responded to standard treatment. The treatment targets and damages cancer cells while trying to spare healthy tissue.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This trial uses a radioactive medicine called MIBG to target and kill neuroblastoma or related tumor cells that have not responded to standard treatments. It may help patients whose cancer has come back or is hard to treat.
This trial gives a radioactive drug called 131-I-MIBG to treat neuroblastoma that has not gone away or has come back. The drug targets cancer cells, and stem cells are given back after treatment to help the body recover.
This trial tests a new type of radiation therapy for advanced neuroendocrine cancers that have not responded to standard treatments. It aims to see if this therapy can help shrink or control the cancer.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.